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HIV-1 replication may continue during antiretroviral therapy (ART)
in some infected individuals resulting in the emergence of drug
resistance mutations and viral evolution (Chun et al., 2005, 2008;
Furtado et al., 1999; Zhang et al., 1999; Zhu et al., 2002;Martinez-Picado
et al., 2000; Palmer et al., 2008; Shen and Siliciano, 2008; Marsden and
Zack, 2009; Quan et al., 2008). Combination antiretroviral therapy
(cART) has been successful in suppressing HIV-1 to undetectable levels
and in reducing illness and death in many individuals (Hirsch et al.,
2008). A signiﬁcant fraction of patients, however, experience virologic
failure while on cART (Ledergerber et al., 1999;Mezzaroma et al., 1999;
Napravnik et al., 2005; Deeks et al., 2000). Characterizing the residual
virus in plasma during cART is a high priority for improving the
understanding of HIV-1 pathogenesis and therapy.
The selective pressures on HIV-1 are applied by ART and by the
immune response (Napravnik et al., 2005; Goetz et al., 2006; Riddle et
al., 2006; Shankarappa et al., 1999; Cofﬁn, 1995; Kuiken et al., 2009;
Hermankova et al., 2001; Harrington et al., 2007; Bagnarelli et al.,
1999; Blay et al., 2006). Previous analyses of HIV-1 in differentanatomic sites within an individual demonstrated compartmentali-
zation, with viral sequences from each site distinct yet phylogenet-
ically related (Kemal et al., 2007; Wong et al., 1997; Singh et al., 1999;
Zhang et al., 2002; Kemal et al., 2003; Philpott et al., 2005; Nickle et al.,
2003; De Pasquale et al., 2003).
Antiretroviral agents may differ in their availability or activity in
different tissues and anatomic sites (Solas et al., 2003; Taylor et al.,
1999; Nettles et al., 2006). Subtherapeutic drug levels in particular
compartments may select for drug resistance mutations in those sites
of viral replication (Hirsch et al., 2008; Johnson et al., 2007).
Coreceptor usage by HIV-1 (tropism) plays a critical role in
pathogenesis, disease progression, and viral tropism for particular cell
types (Ray and Doms, 2006; Lederman et al., 2006; Kreisberg et al.,
2001; Björndal et al., 1997; Blaak et al., 2000; Cheng-Mayer et al.,
2009; Weiser et al., 2008). In patients who have detectable CXCR4-
tropic (X4) viruses in plasma, CCR5-tropic (R5) viruses usually coexist
in the viral swarm (Scarlatti et al., 1997; Freel et al., 2003). We
previously demonstrated that initiation of cART can lead to a
preferential suppression of X4 strains, resulting in a residual virus
population that predominantly uses coreceptor CCR5 (Philpott et al.,
2001). In patients who have not received cART changes in tropism
have been found to result from accumulated mutations in the HIV-1
envelope (Coetzer et al., 2008), and by recombination involving the
V3 region of the envelope (Kemal et al., 2003).
Table 1A
Virologic and clinical characteristics of subject WC4.
Sample IDa/
variant
Tropism of 6.6 kb sequences, Nb Genotypic resistance-associated mutations
R5 X4 Protease RT Resistance interpretation
WC4P-0995: VL, log10 5.7; CD4, 28 cells/mm
3; ART prescribed, None
9 3
WC4P-0995-3 R5 None L74V ddI-R
WC4P-0995-8 R5 None L74V ddI-R
WC4P-0995-9 R5 None T69D, V179A ddC-R
WC4P-0995-5 X4 None L74V ddI-R
WC4P-0995-6 X4 None None No resistance
WC4P-0296: VL, log10 4.94; CD4, 42 cells/mm
3; ART prescribed, 3TC
2 2
WC4P-0296-1 R5 None None No resistance
WC4P-0296-3 R5 None T69A, M184V 3TC-R
WC4P-0296-2 X4 None L74V, M184V ddI-R, 3TC-R
WC4P-0296-4 X4 None None No resistance
WC4P-0896: VL, log10 5.27; CD4, 25 cells/mm
3; ART prescribed, d4T, 3TC
6 0
WC4P-0896-3 R5 None L74V, M184V ddI-R, 3TC-R
WC4P-0896-4 R5 None T69A No resistance
WC4P-0896-5 R5 None T69D ddC-R
WC4P-0896-8 R5 None L74V, M184V ddI-R, 3TC-R
WC4P-0397: VL, log10 5.61; CD4, 10 cells/mm
3; ART prescribed, d4T, 3TC, IDV
6 3
WC4P-0397-1 R5 None None No resistance
WC4P-0397-5 R5 None T69A No resistance
WC4P-0397-6 R5 None None No resistance
WC4P-0397-4 X4 None None No resistance
WC4P-0397-8 X4 None None No resistance
WC4P0897: VL, log10 5.81; CD4, 0 cells/mm
3; ART prescribed, AZT, 3TC, NFV
6 3
WC4P-0897-1 R5 None None No resistance
WC4P-0897-3 R5 None None No resistance
WC4P-0897-5 R5 None None No resistance
WC4P-0897-10 X4 None None No resistance
WC4P-0897-14 X4 None None No resistance
WC4P-0798: VL, log10 4.75; CD4, 97 cells/mm
3; ART prescribed, AZT, 3TC, NFV
2 6
WC4P-0798-3 R5 D30N, N88D K70R, M184V NFV-R, 3TC-R
WC4P-0798-8 R5 D30N, N88D K70R, M184V NFV-R, 3TC-R
WC4P-0798-1 X4 D30N, N88D K70R, M184V NFV-R, 3TC-R
WC4P-0798-5 X4 D30N, N88D M184V NFV-R, 3TC-R
WC4P-0399: VL, log10 5.63; CD4, 108 cells/mm
3; ART prescribed, AZT, 3TC, NFV
2 8
WC4P-0399-3 R5 D30, A71V, N88D D67N, K70R, K103N, AZT-REVT, 3TC-R, NFV-R, NNRTI-R
M184V, T215A, K219Q
WC4P-0399-11 R5 D30, A71V, N88D D67N, K70R, M184V, K219Q AZT-REVT, 3TC-R, NFV-R
WC4P-0399-2 X4 D30N, N88D K70R, M184V 3TC-R, NFV-R
WC4P-0399-5 X4 D30N, A71V, N88D K103N, M184V 3TC-R, NFV-R, NNRTI-R
WC4P-0399-10 X4 D30N, A71V, N88D K70R, V108I, M184V 3TC-R, NFV-R, NNRTI-LLR
WC4P-1299: VL, log10 5.5; CD4, 58 cells/mm
3; ART prescribed, ABC, RTV, IDV, NVP
8 6
WC4P-1299-1 R5 None None No Resistance
WC4P-1299-16 R5 None None No Resistance
WC4P-1299-3 X4 None None No Resistance
WC4P-1299-4 X4 None None No Resistance
WC4P-1299-5 X4 None None No Resistance
WC4P-1000: VL, log10 5.87; CD4, NA
c; ART prescribed, ABC, d4T, RTV, IDV, NVP
8 2
WC4P-1000-1 R5 None K103N NNRTI-R
WC4P-1000-2 R5 None K103N NNRTI-R
WC4P-1000-5 R5 None K103N, K219Q NNRTI-R
WC4P-1000-6 R5 None K103N NNRTI-R
WC4P-1000-7 R5 None K103N NNRTI-R
WC4P-1000-10 R5 None K103N NNRTI-R
WC4P-1000-8 X4 None K103N NNRTI-R
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point mutations, recombination may contribute even more to viral
evolution because it can lead to leaps in genetic evolution by bringing
together two or more distinct beneﬁcial mutations into a single
genome (Malim and Emerman, 2001; Jung et al., 2002; Kemal et al.,
2003; Philpott et al., 2005; Jetzt et al., 2000; Zhuang et al., 2002; Levy
et al., 2004; Chen et al., 2005; Galetto et al., 2004; Shriner et al., 2004;
Charpentier et al., 2006; Rousseau et al., 2007; Templeton et al., 2009).
For recombination to occur, a host cell must be dually infected by
different viruses, each producing progeny RNA's. The distinct progeny
RNA'smust then undergo packaging together in one virion. During the
next round of replication, the reverse transcriptase (RT) switches
from one template to another, resulting in a chimeric molecule
composed of sequences from the two distinct parental genomes (Jetzt
et al., 2000). Longitudinal studies of HIV-1 recombination in infected
individuals have mostly focused on patients not receiving ART (Fang
et al., 2004; Liu et al., 2002; Mild et al., 2007; van Rij et al., 2003).
The evolution of HIV-1 envelope (env) sequences in patients
taking ART has been examined by using Bayesianmethods (Kitchen et
al., 2004) and heteroduplex tracking assays (Kitrinos et al., 2005).
Most studies of the evolution of HIV-1 drug resistance mutations in
patients taking ART however have examined only pol. Investigation of
the evolution of drug resistance needs to examine env as well as pol ,
because HIV-1 tropism, encoded by the V3 region in gp120 (Hung
et al., 1999; Resch et al., 2001; Jensen et al., 2003; Ho et al., 2005;
Cardozo et al., 2007; Poveda et al., 2007), plays a role in directing HIV-
1 to tissues and compartments that may have different ART activity
and selective pressure than is present in blood. A recent paper ex-
amined drug resistance and tropism in plasma from viremic patients
with subtype C HIV-1 who were taking non-suppressive ART. The
methods involved assays of the viral population (Kassaye et al., 2009).
Because HIV-1 exists as a swarm of related yet distinct viral species in
infected people, in order to examine the relationship of pol and env
sequences on the same viral genome it is necessary to study individual
viral variants that span pol through gp120 (Kemal et al., 2007; Palmer
et al., 2008; Salazar-Gonzales et al., 2008; Kieffer et al., 2004).
We aimed to address the following questions regarding the
evolution of residual plasma virus in viremic patients taking cART:
1. Does all of the residual plasma virus obtained from patients taking
cART harbor drug resistance-associated mutations?
2. Is the evolution of drug resistance-associated mutations in pol
associated with HIV-1 tropism?
3. Does viral recombination play a signiﬁcant role in the evolution of
pol and env sequences in patients taking cART?
To address these questions we used a limiting dilution RT-PCR
method to analyze pol and env sequences from individual HIV-1
subtype B variants obtained from serial plasma specimens from four
viremic patients taking cART.
Results
We aimed to examine the evolution of HIV-1 pol and env genomic
sequences derived from serial patient plasma specimens. To achieve
that end it is useful to study DNA fragments spanning pol through
gp120 obtained from individual viral variants.Notes to Table 1A:
Note. VL, viral load log10 RNA copies/ml; 3TC, lamivudine; ABC, abacavir; AZT, zidovudine;
nevirapine; RTV, ritonavir; SQV, saquinavir; ART, antiretroviral therapy; NNRTI, non-n
resistance; LLR, low level resistance; REVT, revertant;
a Sample ID: WC stands for Wadsworth Center, numbers indicate patient number, P st
numbers following month and year of sample are variant numbers.
b Numbers under R5 and X4 columns are the number of R5 and X4 variants as predic
complete 6.6 kb fragment were obtained only for those R5 and X4 variants listed.
c NA, not available.We developed a limiting dilution approach to amplify individual
HIV-1 variants from plasma, and validated its ability to isolate single
viral variants for PCR ampliﬁcation. We designed a 6.6 kb RT-PCR
method that ampliﬁed the HIV-1 genome spanning pol through gp120
(see Materials and methods).
We obtained HIV-1 strains from serial plasma specimens from four
viremic subjects in the Women's Interagency HIV Study (WIHS), a
longitudinal investigation of HIV-1 infection of women (Anastos et al.,
2000). At the start of the study, three of the four subjects (WC2, WC4,
WC51) were untreated, and one (WC9) had received a two-drug
antiretroviral regimen. At the outset none of the subjects had evi-
dence of high level multidrug resistance, but over time they devel-
oped changes in HIV-1 drug resistance patterns following initiation or
change of ART. The antiretroviral regimen varied over time for each
patient, and the patients were prescribed different regimens.
Sequence analysis of eachvariantwasﬁrst performed in theV3 region
of gp120 in order to predict its tropism (Hung et al., 1999; Resch et al.,
2001;Kemal et al., 2007; Cardozoet al., 2007). A total of 122viral variants
with predicted tropism were obtained from the four subjects. The
sequences of pol (protease and reverse transcriptase) and gp120 were
determined from each variant, and several variants were sequenced
entirely from pol through gp120. Drug resistance-associated mutations
were determined based on the protease and reverse transcriptase (RT)
sequences (Johnson et al., 2007; http://hivdb.stanford.edu).
The virologic and clinical characteristics of subjectsWC4 andWC2 at
each timepoint are shown inTables 1A(forWC4)and1B (forWC2). Two
other tables, from subjects WC9 and WC51, are shown in the
Supplementary material. The tables indicate at each timepoint the
plasma HIV-1 RNA load, CD4+T cell count, ART prescribed, the number
of viral variants predicted to use R5 or X4, and the drug resistance
patterns. For each variant studied the sample identiﬁer indicates the
patient's identiﬁer, date, and variant number. The genotypic resistance-
associated mutations and resistance interpretations are shown in
Tables 1A and 1B (Johnson et al., 2007; http://hivdb.stanford.edu). A
total of 25 timepoints were studied from the four subjects. The subjects
were viremic at every timepoint, even though ART was prescribed at
almost all timepoints. The plasma viral load ranged from3.68 log to 6.36
log HIV RNA copies/ml. The tables illustrate that at the start of the study
all four subjects had a mixture of R5 and X4 strains of HIV-1, and there
was no evidence of high-level drug resistance-associated mutations in
pol. Over time, however, multidrug resistance-associated mutations
emerged in some variants from all subjects.
In total, 122 variants, 6.6 kb in size, were characterized for
predicted tropism and genotypic resistance from serial specimens
from the four patients. Table 2 presents the results from each patient,
indicating the number of variants of each tropism, R5 or X4, and the
percentage of variants of each tropism that had high-level genotypic
drug resistance to any antiretroviral drug that targets pol. There were
55 strains from the four subjects that were predicted to be X4-tropic,
71% of which had high-level resistance mutations. There were 67 R5
variants from the four subjects, and 69% of them had high-level
resistance mutations. There was no signiﬁcant association found
between resistance mutations in pol and viral tropism by using
Fisher's Exact test and the binomial test for proportions.
The lack of association between resistance mutations and tropism
prompted us to examine the sequences of pol and gp120 by using
computational methods. Figs. 1 and 2 present phylogenetic trees ofd4T, stavudine; ddC, zalcitabine; ddI, didanosine; IDV, indinavir; NFV, nelﬁnavir; NVP,
ucleoside reverse-transcriptase inhibitors; RT, reverse transcriptase; R, high-level
ands for plasma, numbers following the dash are month and year sample collected;
ted by V3 sequences of the 6.6 kb fragment. Sequences of pol and gp120 from the
Table 1B
Virologic and clinical characteristics of subject WC2.
Sample IDa/
Variant
Tropism of 6.6 kb
sequences, Nb
Genotypic resistance associated mutations
R5 X4 Protease RT Resistance interpretation
WC2P-0795: VL, log10 5.28; CD4, 6 cells/mm
3; ART prescribed, None
8 1
WC2P-0795-4 R5 None T69N, K70G ddC-R
WC2P-0795-8 R5 None T69N, K70G ddC-R
WC2P-0795-9 X4 None T69N, K70T ddC-R
WC2P-0296: VL, log10 4.88; CD4, 3 cells/mm
3; ART prescribed, None
13 1
WC2P-0296-1 R5 None T69D ddC-R
WC2P-0296-2 R5 None T69N ddC-R
WC2P-0296-15 X4 None T69N, V108I ddC-R, NNRTI-LLR
WC2P-0896: VL, log10 4.7; CD4, 74 cells/mm
3; ART prescribed, AZT, 3TC
2 2
WC2P-0896-1 R5 None T69N, K70R, M184V ddC-R, 3TC-R
WC2P-0896-2 R5 None T69N, K70R, M184V ddC-R, 3TC-R
WC2P-0896-3 X4 None T69N, K70R, M184V ddC-R, 3TC-R
WC2P-0896-4 X4 None T69N, K70R, M184V ddC-R, 3TC-R
WC2P-0897: VL, log10 4.74; CD4, 90 cells/mm
3; ART prescribed, d4T, 3TC
3 4
WC2P-0897-3 R5 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
WC2P-0897-6 R5 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
WC2P-0897-7 R5 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
WC2P-0897-1 X4 None T69N, K70R, M184V ddC-R, 3TC-R
WC2P-0897-2 X4 None T69N, K70R, M184V ddC-R, 3TC-R
WC2P-0897-4 X4 None D67N, T69N, K70R, V108I, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R, NNRTI-LLR
WC2P-0897-5 X4 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
WC2P-1297: VL, log10 5.43; CD4, NA
c; ART prescribed, d4T, 3TC, SQV
8 2
WC2P-1297-1 R5 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
WC2P-1297-2 R5 None D67S, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
WC2P-1297-5 X4 None D67A, T69N, K70R, V108I, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R, NNRTI-LLR
WC2P-1297-14 X4 None D67A, T69N, K70R, M184V, T215I, K219E AZT-REVT, ddC-R, 3TC-R
WC2P-0798: VL, log10 4.64; CD4, 188 cells/mm
3; ART prescribed, ddI, NFV
7 3
WC2P-0798-1 R5 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
WC2P-0798-2 R5 None D67N, T69N, K70R, V118I, M184V, T215F, K219E AZT/d4T-R,ddC-R, 3TC-R
WC2P-0798-7 R5 None D67N, T69N, K70R, V108I, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R, NNRTI-LLR
WC2P-0798-5 X4 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
WC2P-0798-9 X4 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
Note. VL, viral load log10 RNA copies/ml; 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; d4T, stavudine; ddC, zalcitabine; ddI, didanosine; IDV, indinavir; NFV, nelﬁnavir; NVP,
nevirapine; RTV, ritonavir; SQV, saquinavir; ART, antiretroviral therapy; NNRTI, non-nucleoside reverse-transcriptase inhibitors; RT, reverse transcriptase; R, high-level resistance;
LLR, low level resistance; REVT, revertant;
a Sample ID:WC stands forWadsworth Center, numbers indicate patient number, P stands for plasma, numbers following the dash are month and year sample collected; numbers
following month and year of sample are variant numbers.
b Numbers under R5 and X4 columns are the number of R5 and X4 variants as predicted by V3 sequences of the 6.6 kb fragment. Sequences of pol and gp120 from the complete
6.6 kb fragment were obtained only for those R5 and X4 variants listed.
c NA, not available.
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respectively. The entire 6.6 kb pol-gp120 sequences obtained from
patients WC4 and WC2 were also analyzed phylogenetically.Table 2
Summary of tropism and resistance.
Patient X4
variants, n
Resist.
X4's, n
Resist.
X4's, %
R5
variants, n
Resist.
R5's, n
Resist.
R5's, %
WC4P 17a 10 59 27 17 63
WC2P 12 12 100 14 14 100
WC9P 9 9 100 13 13 100
WC51P 17 8 47 13 2 15
Total 55 39 71 67 46 69
a Numbers indicate individual HIV-1 variants obtained over time from each patient.
The variants were sequenced in gp120 to predict tropism based on V3, and in pol to
identify genotypic drug resistance mutations.Figs. 1A and B illustrate phylogenetic trees of the protease-RT and
gp120 sequences respectively, from patient WC4. The branches in red
indicate HIV-1 variants predicted to be R5-tropic based on the V3
sequence; branches in blue indicate X4-tropic variants. The dates of
the serial sequences are indicated for each variant in its identiﬁer.
Each branch represents a variant that is listed in Table 1A. The pol
sequences seen in Fig. 1A were intermingled in regard to tropism,
displaying a pattern of variation independent of tropism. Fig. 1B
illustrates the phylogenetic tree of gp120 from patient WC4; it
includes the V3 sequence, and shows clustering by tropism. The
envelope sequences still cluster by tropism even when the V3
sequences were removed to ensure against bias from convergent
evolution (data with V3 sequences deleted not shown).
Figs. 2A and B illustrate the trees from protease-RT and gp120
respectively, from patient WC2, with each branch representing a
variant listed in Table 1B. As with WC4, the protease-RT sequences
Fig. 1. Phylogenetic trees of HIV-1 from patient WC4. (A) Protease and RT genes from plasma. The labels in red indicate HIV-1 variants predicted to be R5-tropic based on the V3
sequence; branches in blue indicate X4-tropic variants. The dates of the serial sequences are indicated for each variant in its identiﬁer. Each branch represents a variant that is listed
in Table 1A. (B) Phylogenetic tree of HIV-1 gp120 gene from plasma.
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Fig. 2. Phylogenetic trees of HIV-1 from patient WC2. (A) Protease and RT genes from plasma. The labels in red indicate HIV-1 variants predicted to be R5-tropic based on the V3
sequence; branches in blue indicate X4-tropic variants. The dates of the serial sequences are indicated for each variant in its identiﬁer. Each branch represents a variant that is listed
in Table 1B. (B) Phylogenetic tree of HIV-1 gp120 gene from plasma.
10 B. Shi et al. / Virology 404 (2010) 5–20from WC2 showed a pattern of variation independent of tropism
(Fig. 2A), while the gp120 sequences clustered according to tropism
(Fig. 2B). The gp120 trees of all four patients generally demonstrated
clustering of sequences by tropism, and all gp120 trees shown
included V3 sequences. Tree topology of gp120 was similar for all
subjects when the V3 loop was deleted (data not shown). The
phylogenetic trees of pol and gp120 from patientsWC9 andWC51 had
similar patterns as the trees from the other patients and are shown in
the Supplementary material. We statistically tested for compartmen-
talization (clustering) by using the Slatkin–Maddison test and
obtained a pb0.001 for compartmentalization.
The results of the phylogenetic analyses (Figs. 1 and 2) and the lack
of association of high-level drug resistance mutations with predicted
tropism (Table 2) raised the question of whether recombination
occurred between viral strains within individual patients. Identiﬁca-
tion of intrapatient HIV-1 recombinants has proved challenging due to
the relatedness of the variants (Kemal et al., 2003; Fang et al., 2004;
Philpott et al., 2005). Extensive sequence analysis of individual
variants and advanced computational methods have now made it
more feasible. To identify putative recombinants and the most likely
parental sequences three computational methods were employed.
1. The Bayesian dual multiple change-point framework (Minin et al.,
2005) allows for varying evolutionary rates, selective pressures,
and phylogenetic trees along the sequence alignment, while
providing estimates that include the site and number of recombi-
nation events.2. The SimPlot (Lole et al., 1999) compares related sequences to a
sequence under investigation.
3. The GARD method uses a genetic algorithm to search a multiple-
sequence alignment to detect putative recombinant breakpoints
(Kosakovsky Pond et al., 2006).
Fig. 3 presents an analysis of a putative recombinant, the
sequence of an HIV-1 strain obtained from the plasma of patient
WC4 in March, 1997 (WC4P0397-8: X4-tropic). A table in the ﬁgure
(Fig. 3A) shows the most likely parental sequences that gave rise to
the recombinant; they were identiﬁed as coming from that patient
in September, 1995 (WC4P0995-5: X4-tropic), and August, 1996
(WC4P0896-5: R5-tropic). Viral tropism and drug resistance-
associated mutations are also shown in the table (Fig. 3A). The
recombinant and the parental sequences had very few or no drug
resistance-associated mutations in the protease and RT genes.
Fig. 3B shows the Bayesian dual change-point analysis with
recombination breakpoints in gp120. In addition, the sequence
was identiﬁed as a recombinant by using GARD (data not shown).
The recombination breakpoints that were identiﬁed by Bayesian
analysis were also supported by informative site analysis (Fig. 3B).
Phylogenetically informative sites are plotted by color indicating
which parental strains have the highest posterior support (Fig. 3B).
Fig. 3C presents a SimPlot analysis of the same putative recombinant
variant, WC4P0397-8. The SimPlot supports the view that recom-
bination occurred in gp120 including the V3 region from parental
sequences that differed in tropism. The recombination resulted in a
Fig. 3. HIV-1 recombination in patient WC4. (A) Recombinant WC4P0397-8 and its most likely parental sequences are shown in the table at the top of the ﬁgure with predicted
tropism and drug resistancemutations. (B) A Bayesian analysis of the envelope region of HIV-1 DNA sequences is shown below the table. Sequences that are predicted to be R5-tropic
are shown in red; sequences predicted to be X4-tropic are in blue. An informative site analysis with similar color coding is shown at the bottom of the ﬁgure. (C) SimPlot of sequences
of the envelope region of recombinant WC4P0397-8 and its most likely parentals. (D) Replication capacity assay of the recombinant WC4P0397-8 and its parentals in comparison to
the control HIV-1 strain pNL4-3.
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two most likely parental sequences.
Fig. 3D shows the results of replication capacity (RC) measure-
ments performed by using the most likely parental and putative
recombinant sequences shown in Figs. 3A and B, as well as a positive
control (HIV-1 pNL4-3). We developed an HIV-1 RC assay to be able to
measure the RC of different viral variants based on the pol gene
ampliﬁed from the patient. The RC assay involved construction of
10 kb chimeric HIV-1 molecules followed by transfection into a cell
line. The chimeric molecules were formed by using ligation-mediatedrecombination PCR. We used HIV-1 pNL4-3 as a backbone with
insertion of the entire pol gene ampliﬁed from plasma-derived virus
by RT-PCR (Fig. 4, Materials and methods). The putative recombinant,
WC4P0397-8, had no resistance-associated mutations in pol, while
the two most likely parental strains had resistance-associated
mutations in RT (Fig. 3A). The recombinant had a much greater RC
than the parentals. The signiﬁcantly greater RC of the recombinant
compared to the parental sequences supports the interpretation that
WC4P0397-8 was a genuine in vivo recombinant that had a survival
advantage over the parentals.
Fig. 4. Replication capacity (RC) assay. The RC assay was based on transfection of a 10 kb chimeric molecular clone, which was constructed by using ligation-mediated recombination
PCR. HIV-1 pNL4-3 was used as a backbone with insertion of the entire pol gene ampliﬁed from plasma-derived virus by RT-PCR.
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another recombinant variant, WC4P0896-8, and its most likely
parental sequences from the same patient, WC4. Fig. 5A is a table
listing the putative recombinant and the likely parental sequences,
their predicted tropism, and drug resistance mutations. Recombi-
nation was conﬁrmed by using Bayesian analysis (data not shown).
The SimPlot (Fig. 5B) and sequence alignment (Fig. 5C) show shared
mutations, indicating that the virus with the M184V drug resistance
mutation in pol and R5 tropism in the V3 region of env (WC4P0896-
8: R5-tropic) was most likely derived from two viruses, one with the
M184V mutation (WC4P0296-2: X4-tropic) and one with the R5
tropism (WC4P0896-4: R5-tropic). More shared mutations are seen
in the sequence alignment further illustrating recombination. The
recombinant WC4P0896-8 shared 8 other base changes in pol with
the parental sequence WC4P0296-2, in addition to the M184V
codon (6 of the base changes are shown in the ﬁgure). In the V3
region of gp120, WC4P0896-8 shared many other base changes with
the parental WC4P0896-4 besides the ones relevant for coreceptor
use. These data illustrate recombination breakpoints between pol
and env.
Fig. 6 presents analyses from another patient, WC2, of the
sequence of a putative recombinant (WC2P0896-4: X4-tropic) and
its most likely parental sequences (WC2P0296-15: X4-tropic; and
WC2P0896-2: R5-tropic). Fig. 6A shows a table with the tropism and
drug resistance mutations of the parental and recombinant variants.In Fig. 6B a Bayesian analysis illustrates that WC2P0896-4 is a re-
combinant formed most likely from the identiﬁed parental sequences
with breakpoints in pol and env. Recombination was supported by
a color-coded informative site analysis at the bottom of Fig. 6B.
Recombination was also identiﬁed by using GARD (data not shown).
The SimPlot shown in Fig. 6C shows breakpoints in pol and gp120. The
recombinant WC2P0896-4 appears to have acquired drug resistance-
associated mutations in pol from one parental (WC2P0896-2) and the
tropism from the other parental sequence (WC2P0296-15). Fig. 6D
shows the RC of the most likely parental and recombinant se-
quences, with the recombinant having an RC approximately 7 times
that of one parental (WC2P0896-2) and 40% that of the other pa-
rental sequence (WC2P0296-15). Both parental sequences had drug
resistance-associated mutations, but the parental with the higher RC
(WC2P0296-15) had two drug resistance mutations in the RT
conferring resistance to only one antiretroviral drug, ddC. The other
parental sequence (WC2P0896-2) and the recombinant, WC2P0896-
4, had the same three resistance-associated mutations, and they were
interpreted as being resistant to two drugs, ddC and 3TC. The parental
strain (WC2P0896-2) had a very low RC, possibly due, at least in part,
to the drug resistance mutations. The recombinant, which had the
same resistance mutations, had a higher RC, possibly due to other
sequences in pol that were not in the drug resistant parental but were
acquired from the other parental by recombination. The recombinant
is likely to have a survival advantage over the parental with the low
Fig. 5. Additional HIV-1 recombination in patient WC4. (A) Recombinant WC4P0896-8 and its most likely parental sequences are shown in a table with predicted tropism and drug
resistance mutations. (B) SimPlot of pol and env sequences of HIV-1 DNA fragments is shown below the table. (C) A sequence alignment of recombinant WC4P0896-8 and its most
likely parental sequences in portions of pol and gp120 is shown below the SimPlot.
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recombinant strain formed in vivo.
The data suggests that all four patients in this study had recom-
binant virus. Data regarding viral recombination in subjects WC9 and
WC51 is presented in the Supplementary material. These data include
tables of virologic and clinical characteristics, phylogentic trees,
SimPlots, and sequence alignments, and show that these subjects, in
addition to subjects WC2 and WC4, also had recombinant HIV-1. All of
the HIV-1 variants described as putative recombinants were conﬁrmedas recombinants by using the Bayesian dual multiple change-point
framework. At least one recombinant was identiﬁed from each patient
that encompassed env and conferred a change in predicted tropism
compared to at least one of its most likely parental strains.
Discussion
In order to improve the therapy of HIV-1 infection it is necessary to
develop a better understanding of the residual virus that persists in
Fig. 6.HIV-1 recombination in patientWC2. (A) Recombinant WC2P0896-4 and its most likely parental sequences are shown in the table with predicted tropism and drug resistance
mutations. (B) A Bayesian analysis of pol and env sequences of HIV-1 DNA is shown below the table. Sequences that are predicted to be R5-tropic are shown in red; sequences
predicted to be X4-tropic are in blue. An informative site analysis with similar color coding is shown at the bottom of the ﬁgure. Tau (τ) represents the marginal posterior
probabilities of themost probable tree topology. That is, the probability of the putative recombinant clustering with tree i at each position. For this case, we used a 5 taxa tree so there
is a topology (which is called “both parentals”which refers to the recombinant clustering with parentals 1 and 2 which had higher posterior support than (1, 5) or (2, 5). This is most
likely due to the fact that both of the parental strains are very similar in this region and we could not distinguish between parentals 1 and 2. (C) SimPlot of pol and env sequences of
the recombinant WC2P0896-4 and its parentals. The window size is 300 bp, and the step size is 20 bp. (D) Replication capacity assay of the recombinant WC2P0896-4 and its
parentals in comparison to the control HIV-1 strain pNL4-3.
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15B. Shi et al. / Virology 404 (2010) 5–20patients who experience virologic failure while taking cART.We asked
whether the residual plasma virus harbored drug resistance muta-
tions in pol and whether the emergence of drug resistance mutations
was associated with tropism. We further evaluated whether viral
recombination played a signiﬁcant role in the evolution of pol and env
in individuals taking cART.
This study examined individual viral variant genomic sequences
derived from serial plasma specimens from four patients who failed to
fully suppress viremia while cART was prescribed. The viral loads
remained high, perhaps due to inadequate adherence with the
therapy by the patients. At the outset all patients had a mixture of
R5 and X4 strains of HIV-1 detected without high-level multidrug
resistance mutations detected in pol. Over time, multidrug resistance-
associated mutations did emerge in all patients.
To perform these analyses on single viral variants we developed
a limiting dilution long RT-PCR method that was characterized
and shown to isolate individual viral variant genomes for direct
sequencing. This technique helped avoid selection bias and PCR
artifacts. Several measures were taken to avoid potential artifacts
including study of single variants from serial samples, analysis of only
one variant at a time (Kemal et al., 2007), and procedures to minimize
PCR-mediated recombination (Fang et al., 1998). By using these
methods we obtained 122 unique 6.6 kb amplicons from the four
subjects over time and sequenced the pol and gp120 genes.
Approximately 70% of the variants had high-level drug resistance
mutations, whether theywere predicted to use X4 or R5. Therewas no
signiﬁcant association between high-level drug resistance in pol and
tropism. These results indicate that it is not possible to predict
whether the residual plasma virus is drug resistant or has a particular
tropism without performing an analysis of the specimen. It also
suggests that the evolution of pol and env genes in a viral genome can
occur relatively independently. It likely reﬂects the different selective
pressures exerted by antiretroviral agents which target pol, and the
host environment. A recent paper used multiplex PCR to examine
single-genome sequences from a different compartment, peripheral
blood mononuclear cells (Wagner and Frenkel, 2008). It reported that
69% of X4-tropic strains had drug resistance mutations, while R5-
tropic strains had 48%. In our study of the residual plasma virus,
approximately 70% of X4-tropic strains had resistance mutations.
Phylogenetic trees analyzing pol sequences found them to be
intermingled in regard to tropism, while trees analyzing gp120
sequences found them to cluster according to predicted tropism. The
clustering of gp120 trees according to tropism suggests that the
cellular environment which supports replication of viral strains of one
tropism may exert particular evolutionary pressures on gp120.
In this study viral recombinants were identiﬁed by computational
analysis of the sequences. Recombinants obtained from the same
patient at different times were found to be derived from a common
ancestor in that patient. The recombinants identiﬁed from patient
WC4 in October, 2000 (WC4P1000-8), March, 1997 (WC4P0397-8),
and August,1996 (WC4P0896-8), were derived from a common
ancestor sequence (Figs. 1A and B). This ﬁnding supports the view
that the sequences identiﬁed as recombinants arose in the patient.
The RC assay gave results supporting the identiﬁcation of recom-
binants. In Fig. 3D the signiﬁcantly greater RC of the recombinant,
compared to that of its most likely parental sequences, supports
the interpretation that the sequence WC4P0397-8 was a genuine
recombinant formed in the patient and was likely to have a survival
advantage over the parental sequences. The enhanced RC of that
recombinant may have been due, at least in part, to having no
resistance-associated mutations in pol , while two of the most likely
parental strains had a mutation.
The sequences that were obtained were analyzed by using phy-
logenetic trees and three computational methods to detect recombi-
nation: Bayesian dual multiple change-point framework, SimPlot, and
GARD (Kitchen et al., 2004; Lole et al., 1999; Kosakovsky Pond et al.,2006). The Bayesian phylogenetic-based approach proved to be the
best in delineating recombination breakpoints, showing high accura-
cy. This approach has a great advantage over the other approaches in
detecting ancient recombination events, as the prediction accuracy
was the least dependent on the extent of subsequent substitution. As
suggested by Chan et al. (2006), we used several methods to screen
for recombinants. SimPlot was chosen as it is a widely available and
easy to use screening tool and has nice visually appealing output.
GARD was chosen as it is one of the newer models available and there
is a very nice web-based interface. If these two programs were in
agreement regarding a recombination event, then the sequences were
analyzed using the more computationally intensive but accurate Dual
Brothers. The main crux of the analysis was based on Dual Brothers.
This was done out of completeness and thoroughness and not out of
heterogeneity in the results. These methods do not identify with
certainty the parentals of a putative recombinant. Although several
groups, including ours, are working to solve this problem, the
methods are not currently available. For the analysis, sequence sets
found to contain recombination identiﬁed in SimPlot were used for
further analysis. The permutations of these sequences that were time-
consistent, that is the possible parentals must have been older than
the putative recombinant, were chosen for analysis using the Bayesian
dual change-point model. It is possible that there were unidentiﬁed
variants that were not sequenced that were the true parentals.
However these true parentals would be evolutionarily related to the
parentals identiﬁed in the analysis.
Previous studies of HIV-1 recombination documented frequent
recombination, and found intersubtype recombinants in individuals
living in parts of theworldwheremultiple subtypeswere found (Malim
and Emerman, 2001; Jung et al., 2002; Kemal et al., 2003; Fang et al.,
2004; Philpott et al., 2005; Jetzt et al., 2000; Zhuang et al., 2002; Levy et
al., 2004; Chen et al., 2005; Galetto et al., 2004; Shriner et al., 2004;
Charpentier et al., 2006; Rousseau et al., 2007; Templeton et al., 2009;
Kuiken et al., 2009). The presence of different subtypes facilitates the
identiﬁcation of recombinants. However, relatively few studies have
investigated viral recombination longitudinally in individuals infected
with a single subtype of HIV-1 (Fang et al., 2004; Liu et al., 2002; Mild
et al., 2007; van Rij et al., 2003; Templeton et al., 2009).
One possible factor contributing to the frequency of recombination
may be certain resistance mutations such as the M184I mutation in
the RT gene. This mutation has been found to be associated with an
increase in the rate of RT template switching, resulting in increased
HIV-1 recombination (Nikolenko et al., 2004). We identiﬁed the
M184I mutation in a recombinant ((WC9P0896-9) and one of its
parental sequences (WC9P0896-5) from patient WC9 (data not
shown, available on request).
These analyses of HIV-1 recombination provided some insight into
the frequency of recombination in individual patients. We studied 4
patients infected with subtype B over a period of approximately 1–
5 years and identiﬁed recombinants from all four patients. The
recombinants often had drug resistance-associated mutations in pol.
In each patient we found at least one recombinant that encompassed
env and conferred a change in predicted tropism compared to a
parental strain. These data demonstrate that switches in tropism may
occur commonly and may result from recombination as well as from
accumulated mutations (Coetzer et al., 2008).
The ﬁnding of frequent recombination between R5 and X4 viral
strains indicates that the strains infect some of the same cells, at least
on occasion. This may reﬂect the fact that primary lymphocytes and
macrophages, the main targets of infection in vivo, can express
coreceptors CCR5 and CXCR4 (Goodenow and Collman, 2006).
Conclusions
We demonstrated that changes in viral tropism and the develop-
ment of drug resistance mutations occurred independently of each
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patients studied, suggesting that recombination played a role in the
evolution of HIV-1 strains. Approximately 70% of the serial plasma
viral strains from viremic patients prescribed cART had high-level
drug resistance mutations, whether the strains were R5 or X4 tropic.
Future studies should examine serial specimens from patients to
better deﬁne the role that recombination plays in pathogenesis, the
development of drug resistance, tropism switches, and viral evolution.
Materials and methods
Study population
We obtained serial plasma specimens from participants in the
Bronx–Manhattan site of the Women's Interagency HIV Study
(WIHS), a NIH multicenter study of the natural history of HIV-1
infection in women (Anastos et al., 2000). Specimens from some of
these subjects had previously been examined in a previous study of
coreceptor usage (Philpott et al., 2001). The patient identiﬁers in the
previous studywere coded differently than in the present study. In the
present study we examined specimens from patients WC2, WC4,
WC9, and WC51; the initials WC stand for Wadsworth Center. In the
previous study the same patients were studied and their code
numbers were 2 (WC2 in this study), 7(WC4), 5(WC9), and 4
(WC51). For the present study, subjects were chosen who had serial
specimens with viral loads of at least 4000 RNA copies/ml, and viral
populations that were known to harbor both X4 and R5 strains of HIV-
1. The earliest specimens from these subjects were screened for the
presence of high-level HIV-1 multidrug resistance (MDR), and only
those subjects without evidence of MDR at the initial time point were
selected for longitudinal investigation.
To initially screen these specimens for antiretroviral drug
resistance mutations, total RNA was extracted from 140 μl of plasma
by using the QIAamp® Viral RNA kit (Qiagen, Inc. Valencia, CA)
according to the manufacturer's instructions. Genotyping of the pol
region was performed by using the TruGene™ HIV-1 Genotyping Kit
(Siemens Healthcare Diagnostics, Deerﬁeld, IL) according to the
manufacturer's recommendations.
Ampliﬁcation
Reverse transcription (RT) and long RT-PCR were performed by
using methods established by our lab (Fang et al., 1998) to minimize
the potential for PCR-mediated recombination. We also used end-
point limiting dilution methods to avoid artifactual PCR recombina-
tion and resampling (Kemal et al., 2007; Liu et al., 1996). TRIzol LS
Reagent (Invitrogen, Carlsbad, CA) was used in RNA extraction.
Following the manufacturer's instructions, 250 μl patient plasma was
used in each experiment and ﬁnally RNA was dissolved in 20 μl of
RNase-free H2O.
The SuperScript™ III First-Strand Synthesis System for RT-PCR
(Invitrogen, Carlsbad, CA) was used. The reverse transcription
included 5 μl RNA, 2 U SuperScript™ III, and 1 μl 50 μΜ oligo (dT) 20
as RT primer in a total 20 μl reaction. The RT reaction was carried out
at 50 °C for 60 min. The long RT time was chosen to yield complete
cDNA. Following the manufacturer's instructions, cDNA was treated
with 1 μl RNase H before the next PCR step, or it was stored at−20 °C.
A nested PCR was used to amplify a 6625 bp HIV-1 DNA fragment
which starts before the pol gene and ends after gp120 (1319–7944 nt
positions, according to HXB2). The ﬁrst PCR primer pair was F1309
(forward) 5′-GCATTATCAGAAGGAGCCAC-3′ and R8065 (reverse) 5′-
CAACTAGCATTCCAAGGCAC-3′; the second PCR primer pair was F1319
(forward) 5′-AAGGAGCCACCCCACAAG -3′ and R7944 (reverse) 5′-
TGATGCCCCAGACTGTGAG-3′. The GeneAmp XL PCR kit and a hot start
PCR with AmpliWax PCR Gem100 (Applied Biosystems, Foster City,
CA) were used following the manufacturer's instructions. The ﬁnalprimer concentration was 0.2 μM, and the optimized Mg(OAc)2
concentration was 0.875 mM. Thermal cycling parameters were as
follows: 94 °C, 1min for preheat; then 20 cycles of 94 °C for 15s, 60 °C
for 6min; then another 15 cycles of 94 °C for 15 s, 60 °C for 6min with
10 s extension increase per cycle; with ﬁnal extension at 72 °C for
10min, then hold at 4 °C. Extra extension time was added after 20
cycles to ensure the synthesis of the full length amplicon. The ﬁrst PCR
used 3 μl of cDNA at end-point dilution as template. For the second
PCR, 3 μl of the ﬁrst PCR product was used as template.
Limiting dilution PCR
We developed a limiting dilution approach to amplify individual
HIV-1 variants. To estimate the sensitivity of this 6.6 kb RT-PCR, we
applied the parametric model (Hughes and Totten, 2003). Serial end-
point dilution PCR was performed by using known copy numbers of
HIV-1 pNL4-3 as template, and a sensitivity curve was drawn
(Fig. 7A). The parametric model was plotted along with the empirical
sensitivity at each concentration. The parametric model showed a
very good ﬁt with our experimental data. Based on the model we
found that when the 6.6 kb PCR sensitivity approaches a single copy of
template, the probability of a positive reaction is 0.405.
To evaluate the ability of the limiting dilution PCR method to
isolate single viral genomes for ampliﬁcation, differences in restriction
fragment length polymorphism (RFLP) patterns among known strains
of HIV-1 were examined. Four HIV-1 strains, LAV, SF162, RFV82F/
I84V, and Donor E, were chosen because their 6625 bp RT-PCR
product had different RFLP patterns after digestion by restriction
endonuclease NheI. The strains were obtained from the NIH AIDS
Reference and Reagent Program (www.aidsreagent.org). A mixture of
equal quantities of these four virus strains was prepared. After RNA
extraction and RT, limiting dilution PCR was performed by using the
RT product as template. The positive PCR products were gel puriﬁed,
and then 200 ng of puriﬁed PCR product was digested with 5 U of
restriction enzyme NheI (New England Biolabs, Ipswich, MA) at 37 °C
for 1 h. RFLPs were analyzed by using 1% agarose gel electrophoresis.
Fig. 7B shows the examples of ampliﬁcation of a 6.6 kb PCR when
using template from two different dilutions of the mixed HIV-1
strains. The DNA was subjected to 1% agarose gel electrophoresis.
Lanes 1–5, ampliﬁed from a relatively high concentration of the virus
mixture, had a 100% probability of positive reactions, and lanes 6–14,
ampliﬁed from a lower concentration of the virus mixture, had a 39%
probability of detection (end-point dilution). The corresponding
positive PCR products in each lane were then digested with Nhe I
(Fig. 7C) and subjected to 1% agarose gel electrophoresis. Lanes 1–5
illustrate the RFLP pattern of samples containing the mixed strains.
Lanes 6–14 show the RFLP pattern of individual strains, which
indicates that the template in this PCR experiment was from a single
HIV genome.
Sequence analysis
We studied unique 6.6 kb amplicons extending from pol through
gp120 obtained from single HIV-1 genomes by using limiting dilution
RT-PCR. Sequences were determined by direct sequencing from PCR
products. Direct sequencing was used instead of molecular cloning to
avoid the potential inefﬁciency that could result from attempting to
clone such large fragments. Efforts were also made to avoid PCR-
mediated recombination and other artifacts (Fang et al., 1998, 2004;
Kemal et al., 2003, 2007; Philpott et al., 2005). All sequence data were
carefully checked for the presence of multiple peaks. In rare cases,
when multiple peaks were found, those sequences were excluded
from the ﬁnal analysis. Computational analyses, including a BLAST
search, and phylogenetic analysis of the sequences showed no
evidence of contamination, and open reading frames were intact,
Fig. 7. Analysis of limiting dilution PCR using a parametric model. (A) The sensitivity curve from the parametric model is shown in the solid line, and the empirical sensitivity of PCR
at each dilution is shown in circles. (B) End-point limiting dilution PCR. Four HIV-1 strains that differ in restriction fragment length polymorphisms (RFLP) when their PCR product
was digested by the restriction enzyme Nhe I (HIV-1 strains LAV, SF162, RF-V82F/I84V, and patient donor E) were mixed in known quantities. The DNA was subjected to 1% agarose
gel electrophoresis. The left end of the gel (a: lanes1–5) shows the 4 HIV-1 strains after a minimal 1/50 dilution. The right end of the gel (b: lanes 6–14) illustrates an end-point
dilution (1/500 dilution of the cDNAmixture), yielding a positive PCR in less than 40% of equivalent dilutions. (C) RFLP. The diluted cDNAwas digestedwith Nhe I and subjected to 1%
agarose gel electrophoresis. Lanes 1–5 (a) illustrate the gel pattern of lanes containing the mixed strains at the 1/50 dilution after digestion by Nhe I . Lanes 6–14(b) indicate, based
on the gel pattern after Nhe I digestion, that the ﬁnal 1/500 dilutions of the original mixture of 4 strains contained only one viral strain per lane.
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sequences were identiﬁed as HIV-1 subtype B.
Coreceptor usage prediction algorithm
To predict HIV-1 coreceptor usage (tropism), we applied three
different algorithms:
A. The method validated in our lab on the basis of the overall charge
of the V3 loop and the presence of basic or acidic residues at
positions 275 and 287 of the env gene as described (Bhattacharyya
et al., 1996; Hung et al., 1999; Philpott et al., 2001).B. A modiﬁed prediction method based on the 3D molecular
modeling of the HIV-1 V3 loops (Cardozo et al., 2007). The study
by Cardozo et al. showed a 94% concordance between genotypic
prediction and cell-based phenotypic analysis.
C. A web-based bioinformatic method based on scoring of position-
speciﬁc scoring matrices (PSSM) (Jensen et al., 2003).
Genotypic drug resistance
Drug resistance was predicted by using the Stanford HIV drug-
resistance database (http://hivdb.stanford.edu) for interpretation of
genotype data. Results reported here are based on February, 2008
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International AIDS Society-USA Drug Resistance Mutations Group
guidelines for interpretation of resistance mutations (Hirsch et al.,
2008; Johnson et al., 2007).
HIV-1 replication capacity assay
We developed an HIV-1 replication capacity (RC) assay to be able
to measure the RC of different viral variants. The RC assay was based
on construction of 10 kb chimeric HIV-1 molecules followed by
transfection into a cell line. The chimeric molecules were formed by
using ligation-mediated recombination PCR. We used HIV-1 pNL4-3
as a backbone with insertion of the entire pol gene ampliﬁed from
plasma-derived virus by RT-PCR (Fig. 4). To perform a 3 way ligation-
mediated recombination PCR, two fragments were made from HIV-1
pNL4-3 serving as a backbone. The 5′ end fragment was constructed
by digestion of the plasmid pNL-5END (a pNL4-3 5′ end clone,
includes the 5′ LTR to 2048nt, according to HIV-1 HXB2) by restriction
enzymes Sph I and Sma I. The 3′ END fragment was prepared by
digestion of pNL-3END (a pNL4-3 3′ end clone, includes 5245 nt to the
3′ LTR, according to HXB2) by EcoR I and Sma I. The third fragment
containing the full length HIV-1 pol gene was obtained from patient
plasma viral RNA by RT-PCR. The 6 kb RT-PCR products were double
digested by both Sph I and EcoR I and then gel puriﬁed. The ligation
product was used as template for a 10 kb PCR to generate chimeric
HIV-1 complete genomic DNA. The insertion was conﬁrmed by
sequencing the cross-over region of the 10 kb PCR product. Cultured
293T cells (Invitrogen) were transfected with puriﬁed 10 kb DNA by
using FuGENE 6 Transfection Reagent (Roche Applied Science,
Indianapolis, IN) following the manufacturer's instructions. After
72 h in culture, the supernatant was aliquoted, and stored at −80 °C
until use.
Virus production from the transfected 293T cells was quantitated
in JC53-bl cells. JC53-bl is a HeLa-based cell line that has been
genetically engineered to stably express high levels of CD4, CXCR4,
and CCR5 and is susceptible to infection by diverse isolates of HIV-1
(www.aidsreagent.org). The ß-Gal and luciferase genes were intro-
duced into JC53-bl cells separately, each under transcriptional control
of the HIV-1 long terminal repeat. The ß-Gal reporter was included to
allow direct enumeration of infectious viral units by counting ß-Gal
expression-positive infected cell colonies under a microscope. The
luciferase reporter enables automated quantitation of HIV infection.
JC53-bl cells were previously analyzed for their susceptibility to
infection with primary HIV-1 isolates. Compared with phytohemag-
glutinin (PHA)-stimulated cultures of peripheral blood mononuclear
cells (PBMC), the JC53-bl cells were at least 2–5 fold more sensitive to
infection with primary HIV-1 isolates than PHA-stimulated PBMCs
(Wei et al., 2002).
Inourexperiments, the infectious titer of thevirus in the supernatant
obtained from the transfected 293T cells was determined by infecting
JC53-bl cells with a range of viral dilutions in a 24-well plate. The cells
were stained for ß-galactosidase expression 48 h postinfection by using
the In Situ β-Galactosidase Staining Kit (Stratagene, La Jolla, CA). Viral
infectious units were determined by counting the number of blue cells
under a microscope, using dilutions that gave between 200 and 600
stained cells (Kimpton and Emerman, 1992).
Recombinant virus variants of the same infectious titer were used
to infect 1×104 JC53-bl cells in 24-well tissue culture plates. At 72 h
postinfection, the supernatant was removed and the cells were lysed
by using a luciferase assay system kit (Promega, Madison, WI.). The
light intensity of each cell lysate was measured on a TD-20/20
luminometer (Turner Biosystems, Sunnyvale, CA). Mock-infected
wells were used to determine background luminescence, which was
subtracted from the sample wells. This 10 kb chimeric HIV-1 DNA
produced recombinant HIV-1 virus after transfection of 293T cells. We
measured the replication capacity of the recombinant virus in theindicator cell line JC53-bl in the absence of antiretroviral agents by
measuring expression of the luciferase reporter gene and comparing it
to luciferase expression by the control HIV-1 strain pNL4-3 (Barbour
et al., 2002).
Computational methods
Multiple alignments of sequences from patients plus suitable
reference sequences were assembled with MAFFT and/or CLUSTAL-
W, checked for quality and hand-edited, if necessary, by using BioEdit
software: (http://www.mbio.ncsu.edu/BioEdit/bioedit.html). Prior
to phylogenetic tree construction, columns of the alignment contain-
ing gaps were removed. Maximum likelihood and neighbor-joining
phylogenetic trees were produced using PAUP with the general time
reversible model of evolution and a gamma distribution of site-
speciﬁc rates of evolution. Bootstrap replications (B=100) were used
to assess tree robustness. To ensure against bias from convergent
evolution, envelope trees were also constructed using sequences that
had the V3 loop deleted. The gp120 trees that had the V3 loop deleted
were not shown in the paper or in the Supplementary material.
Intrapatient recombination was detected by using SimPlot (Lole
et al., 1999), the Los Alamos National Laboratory (LANL) HIV Database
Highlighter tool, and GARD. The GARD method uses a genetic algo-
rithm to search a multiple-sequence alignment to detect putative
recombinant breakpoints (Kosakovsky Pond et al., 2006). A more
rigorous recombination analysis was done by using a Bayesian dual
change-point model using Dual Brothers software (Minin et al., 2005).
There are many tools to analyze recombination, each with their own
speciﬁc strengths and drawbacks and limitations. In this case we were
speciﬁcally interested in identifying the breakpoints in the putative
recombinants. The main tool of our analysis was Dual Brothers, the
Bayesianphylogenetic-based approach. InChan et al. (2006), theauthors
examined the predictive accuracy of several recombination detection
programs and showed that Dual Brothers, in particular, were less
sensitive to parameter setting than other methods and had higher
accuracy in locating recombination breakpoints compared to other
approaches.Sequenceswere alignedbyusingClustal-Wandhand-edited
as necessary. For this analysis the V3 loops were included. Phylogenet-
ically informative sites were plotted beneath the posterior probability of
tree support.
Statistics
Fisher's exact test and the binomial test for proportions were used
to assess signiﬁcance. All p-values are two-sided and a p-valueb0.05
was considered signiﬁcant.
Nucleotide sequences
The sequences have been contributed to GenBank and the
following accession numbers were assigned: FJ861709–FJ861830 for
pol gene sequences from subjects WC2, WC4, WC9, WC51; and
FJ861831–FJ861952 for gp120 sequences from subjects WC2, WC4,
WC9, and WC51. For 6 kb sequences from patient WC4 the accession
numbers were FJ861953–FJ861964, and for 6 kb sequences from
patient WC2 the numbers were GQ358530–GQ358532.
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